Next Article in Journal
Marrying Story with Science: The Impact of Outdated and Inconsistent Breast Cancer Screening Practices in Canada
Previous Article in Journal
Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis
Case Report

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review

1
Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland
2
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3531-3539; https://doi.org/10.3390/curroncol29050285
Received: 2 February 2022 / Revised: 25 April 2022 / Accepted: 11 May 2022 / Published: 13 May 2022
(This article belongs to the Section Thoracic Oncology)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)–40–50% and squamous cell carcinoma (SCC)–20–30%. The development of new molecular therapies targeting particular abnormalities such as mutations in the EGFR (Epidermal Growth Factor Receptor) gene or ROS1 or ALK genes rearrangements resolved in novel strategies in advanced NSCLC management. EGFR mutation occurs mostly in patients with ADC and those patients are mostly females with no or light smoking history. The hereby presented patient fitted the ADC characteristics, while they were diagnosed with SCC. The unusual diagnosis implied further genetic testing, which established the occurrence of L858R substitution in exon 21 in the EGFR gene. A 63-year-old female was admitted to the unit due to a dry cough, pain in the right chest area and dyspnoea. When diagnosed, the patient had a peripheral mass in the right lung superior lobe (55 × 40 mm), satellite nodules in the apex of the same lung and packets of disintegrating lymph nodes. Positron Emission Tomography (PET-CT) confirmed a diffuse neoplastic process qualified as stage IV on the TNM scale. Due to EGFR gene mutation, the woman was administered osimertinib, however, the treatment did not succeed, and other therapeutic solutions were undertaken. The patient died 10 months after diagnosis. Patients with advanced ADC harboring EGFR mutation can receive osimertinib, a third-generation tyrosine kinase inhibitor (TKI), however, the use of TKIs in SCC remains controversial. In some published cases, osimertinib treatment led to success, in others, the therapy did not result in the expected final effect. Small sample groups and diverse molecular backgrounds indicate the need for further research in this field. Thus, the treatment decision-making process in those patients overall remains extremely demanding and ambiguous. View Full-Text
Keywords: osimertinib; squamous cell carcinoma; non-small cell lung cancer; EGFR; TKIs osimertinib; squamous cell carcinoma; non-small cell lung cancer; EGFR; TKIs
Show Figures

Figure 1

MDPI and ACS Style

Rekowska, A.; Rola, P.; Wójcik-Superczyńska, M.; Chmielewska, I.; Krawczyk, P.; Milanowski, J. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review. Curr. Oncol. 2022, 29, 3531-3539. https://doi.org/10.3390/curroncol29050285

AMA Style

Rekowska A, Rola P, Wójcik-Superczyńska M, Chmielewska I, Krawczyk P, Milanowski J. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review. Current Oncology. 2022; 29(5):3531-3539. https://doi.org/10.3390/curroncol29050285

Chicago/Turabian Style

Rekowska, Anna, Piotr Rola, Magdalena Wójcik-Superczyńska, Izabela Chmielewska, Paweł Krawczyk, and Janusz Milanowski. 2022. "Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review" Current Oncology 29, no. 5: 3531-3539. https://doi.org/10.3390/curroncol29050285

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop